Last updated: February 23, 2026
What is NDC 42799-0208?
NDC 42799-0208 is a specific formulation of a drug product registered in the National Drug Code (NDC) database. This code corresponds to a branded or generic medication, typically with detailed formulation, dosage, and packaging specifications. Access to exact product details (such as active ingredient, strength, form, manufacturer) is essential for precise market analysis.
Based on current publicly available data, NDC 42799-0208 refers to Kerydin (tavaborole) topical solution 5%, used for the treatment of onychomycosis (fungal nail infection).
Market Size and Key Drivers
Market Scope
The global onychomycosis treatment market was valued at approximately USD 1.2 billion in 2022. It is projected to grow at a Compound Annual Growth Rate (CAGR) of 4.5% through 2028, driven by increasing prevalence, demographic shifts toward aging populations, and expanded adoption of topical and systemic antifungal therapies.
Key Drivers
- Increasing prevalence: Onychomycosis affects roughly 10-15% of the adult population worldwide, with higher incidence in those over 60.
- Aging population: An aging demographic boosts demand for effective topical treatments.
- Advances in formulations: Improved drug formulations with better penetration and fewer side effects promote market penetration.
- Healthcare awareness: Growing awareness and diagnosis rates support market expansion.
- Product approvals: Regulatory approvals for new formulations or indications influence market dynamics.
Competition Overview
- Existing treatments: Oral terbinafine, itraconazole, and topical agents like efinaconazole and tavaborole.
- Market share: Tavaborole holds approximately 20%± of the topical market as of 2022, with others including ciclopirox and newer entrants.
- Pipeline products: Investigational drugs focus on enhancing efficacy and reducing treatment duration.
Price Analysis and Projections
Current Pricing Snapshot
- Brand (Kerydin): Retailer prices range from USD 700 to USD 900 per 8-oz bottle (30 mL) as of 2023.
- Generic alternatives: Limited through regulatory pathways; generic prices tend to be lower, around 10-25% below branded products.
Historical Price Trends
- The price of Kerydin has remained relatively stable since its approval in 2014, with minor fluctuations attributable to insurance coverage changes and market competition.
- Generic formulations have historically entered the market 4-6 years post-launch, leading to price reductions.
Market Entry and Price Competition Impact
- Emerging generic products: Expected to reduce average treatment costs by 20-30% within 1-2 years of market entry.
- Formulation improvements: New formulations with enhanced efficacy could command premium pricing due to perceived superior outcomes.
Price Projections (2023-2028)
| Year |
Branded Price Range (USD per 30 mL) |
Expected Generic Price Range (USD per 30 mL) |
Notes |
| 2023 |
700–900 |
500–675 |
Premium pricing persists; generics gaining traction |
| 2024 |
690–880 |
480–660 |
Slight decrease in branded prices as generics enter |
| 2025 |
670–860 |
460–640 |
Increased generic market share expected |
| 2026 |
650–840 |
440–620 |
Competitive pressure intensifies |
| 2027 |
630–820 |
420–600 |
Price stabilization anticipated |
| 2028 |
610–800 |
400–580 |
Maximal generic penetration; prices plateau |
Factors Influencing Pricing
- Regulatory approvals for biosimilar or new formulations.
- Manufacturing costs adjustments.
- Reimbursement policies and payer negotiations.
- Patent expirations removing barriers for generics.
- Market competition and patent litigation outcomes.
Strategic Implications
- Market entry timing: Rapid entry of generics can pressure prices downward.
- Innovation: New formulations with faster onset or higher efficacy could sustain premium pricing.
- Pricing strategies: Manufacturers should assess payer dynamics and formulate competitive yet sustainable price points.
Key Takeaways
- NDC 42799-0208 (tavaborole topical solution) operates within a stable but competitive market.
- The global onychomycosis treatment market shows steady growth, with pharmacoeconomic factors shaping pricing.
- Branded prices hover around USD 700–900; generics are expected to challenge these within 2 years.
- Long-term projections indicate gradual price decline, stabilized by market saturation and therapeutic innovations.
- Strategic positioning depends on timing, formulation improvements, and navigating patent landscapes.
FAQs
What factors most influence the pricing of topical antifungal drugs?
Manufacturing costs, market competition, patent status, regulatory environment, and reimbursement policies.
How does generic entry typically affect drug prices?
It usually reduces prices by 20–30% within 1-2 years, depending on regulatory and market factors.
What is the primary driver of market growth for onychomycosis treatments?
The increasing prevalence among aging populations and improved awareness and diagnosis.
When will generics likely dominate the market for NDC 42799-0208?
Within 2–3 years of patent expiration or approval of biosimilar alternatives.
Are there any regulatory or patent hurdles impacting price projections?
Yes. Patent protections or patent litigations can delay generic competition, maintaining higher prices.
References
[1] Grand View Research. (2022). Onychomycosis Treatment Market Size, Share & Trends Analysis Report. Retrieved from https://www.grandviewresearch.com/industry-analysis/onychomycosis-treatment-market
[2] U.S. Food & Drug Administration (FDA). (2014). FDA approves Tavaborole for fungal toenail infections. Available at https://www.fda.gov/news-events/press-announcements/fda-approves-tavaborole-fungal-toe-nail-infections
[3] IQVIA. (2022). Topical Antifungal Market Data.
[4] MarketWatch. (2023). Price trends for Kerydin (tavaborole). Available at https://www.marketwatch.com
[5] FDA Patent Database. (2023). Patent status for tavaborole.
